Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data

BACKGROUND: S-1 has been recognized as one of the standard adjuvant chemotherapies for pancreatic ductal adenocarcinoma (PDAC) in East Asia, but the optimal adjuvant chemotherapy regimen has not been determined. We aimed to compare the efficacy and safety of adjuvant gemcitabine plus S-1 (GS) with S...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hui, Qiao, Caixia, Lu, Jun, Cheng, Yuejuan, Dai, Menghua, Zhang, Taiping, Guo, Junchao, Wang, Yingyi, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587333/
https://www.ncbi.nlm.nih.gov/pubmed/36265240
http://dx.doi.org/10.1016/j.neo.2022.100841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587333/
https://www.ncbi.nlm.nih.gov/pubmed/36265240
http://dx.doi.org/10.1016/j.neo.2022.100841

Ejemplares similares